Concepedia

Ole Kleist Jeppesen

OK

15

Publications

4.8K

Citations

13

H-Index

2009

Active since

Affiliations

Novo Nordisk (Denmark)(Current)

The University of Texas Southwestern Medical Center

Pennington Biomedical Research Center

Cleveland Clinic Lerner College of Medicine

University College London

Ole Kleist Jeppesen is an author at Novo Nordisk (Denmark) specializing in clinical trials, medicine, and diabetes.

Top concepts

Publications per year

2009–2025

15

Publications

15

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.8K citations · Full text

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.2K citations

, , +6

Once-Weekly Semaglutide in Adolescents with Obesity

Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez et al. · New England Journal of Medicine · 2022 · 554 citations · Full text

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi et al. · Diabetes Care · 2019 · 430 citations · Full text

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Donna H. Ryan, Ildiko Lingvay, John Deanfield et al. · Nature Medicine · 2024 · 230 citations · Full text

Rows per page

1–5 of 15